- Home
- NXB vs PDSB Comparison
NXB vs PDSB Comparison
Compare NXB & PDSB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NXB | PDSB |
|---|---|---|
| Founded | 2012 | 2005 |
| Country | United States | United States |
| Employees | N/A | 10 |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.2M | 42.4M |
| IPO Year | 2025 | 2015 |
Fundamental Metrics
Financial Performance| Metric | NXB | PDSB |
|---|---|---|
| Price | $2.00 | $1.34 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $4.75 |
| AVG Volume (30 Days) | 25.4K | ★ 32.0M |
| Earning Date | 11-21-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 28.16 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $119,866,298.00 | N/A |
| Revenue This Year | $41.82 | N/A |
| Revenue Next Year | $29.41 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 21.08 | N/A |
| 52 Week Low | $1.79 | $0.20 |
| 52 Week High | $2.57 | $1.55 |
Technical Indicators
Market Signals| Indicator | NXB | PDSB |
|---|---|---|
| Relative Strength Index (RSI) | 50.27 | 76.55 |
| Support Level | $2.00 | $0.60 |
| Resistance Level | $2.35 | $1.55 |
| Average True Range (ATR) | 0.15 | 0.15 |
| MACD | -0.00 | 0.04 |
| Stochastic Oscillator | 40.00 | 96.30 |
Price Performance
Historical ComparisonAbout NXB NextBoat Inc. Common Stcok
NextBoat Inc focused on AI-powered technology platform designed to modernize and scale the world-wide pre-owned marine marketplace.
About PDSB PDS Biotechnology Corporation
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells. The company has determined that it operates as a single reportable segment, developing a growing pipeline of targeted immunotherapies designed to overcome the limitations of current immunotherapy.